The Role of Pioglitazone in Vascular Transcriptional Remodeling (PREVALENT)
Myocardial Reperfusion Injury
About this trial
This is an interventional prevention trial for Myocardial Reperfusion Injury
Eligibility Criteria
Inclusion Criteria: Male individuals Individuals undergoing CABG surgery for coronary artery disease Be over 40 years of age BMI between 20 and 34.9kg/m2 Non-diabetic or if diabetic, disease duration < 10 years, Hba1c < 8%, non-user of NPH insulin Ejection fraction > 40% Glomerular filtration rate > 45 mL/min Exclusion Criteria: BMI greater than 35 kg/m2, steatohepatitis, chronic kidney disease, systemic vasculitis, conditions that induce systemic inflammation such as psoriasis and systemic lupus erythematosus contraindications to the use of pioglitazone hydrochloride (heart failure, liver failure - AST or ALT > 2.5x upper normal limit, history of bladder cancer or macroscopic hematuria without investigation) moderate or severe valve disease need for concomitant use of other hypoglycemic therapies during hospitalization, particularly insulin peripheral edema recent hospitalization known allergy to any study drug polyuria, polydipsia, weight loss, or other clinical signs of volume depletion or diabetes, difficult-to-control systemic arterial hypertension, defined as individuals taking 4 or more drugs those who withdraw the Informed Consent Form (TCLE), or who, for some reason, are not able to sign or understand the TCLE history of gastrointestinal disorders that may interfere with study drug absorption research participant who is participating in other clinical trials or whose participation ended less than six months ago Research participant who has left ventricular dysfunction
Sites / Locations
- University of CampinasRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Pioglitazone
Placebo
Research participants will be randomized to receive pioglitazone hydrochloride 45mg/day for 5 days prior to coronary artery bypass surgery.
Research participants will be randomized to not receive intervention in the days prior to coronary artery bypass graft surgery.